Introduction ferrin saturation>20% and/or ferritin>200 mg/l. Iron therapy was then stopped for 4 months. Recombinant human erythropoietin ( Erypo, Cilag, Austria) dosage EÃcacy and cost of recombinant human erythropoietin in all patients was stable throughout the last 3 months (rHuEpo) therapy are important issues for nephrologbefore stopping i.v. iron therapy. The target haemoists. Absolute iron deficiency (ferritin<15 mg/l; globin level was between 10 and 12 g/dl. Following uraemic patients on rHuEPO therapy<100 mg/l ) and withdrawal of i.v. iron therapy, the dosage of rHuEpo functional iron deficiency (ferritin normal or suprawas gradually adjusted every 4 weeks to maintain the normal, transferrin saturation<20%, hypochromic red target haemoglobin. blood cell>10%) are the main reasons for rHuEpo hyporesponsiveness. Therefore, careful evaluation of iron parameters is of pivotal importance in chronically Patient 1 (Table 1) uraemic patients before and during rHuEpo therapy.
After more than 12 months of rHuEpo and i.v. iron Nevertheless, the sensitivity and specificity of both saccharate therapy (total iron dosage 3080 mg) the traditional (ferritin concentration, transferrin saturaserum ferritin of patient 1 was 806 mg/l, but a transfertion) and more sophisticated new methods (percentage rin saturation of 16.4% and hypochromic red blood of hypochromic red blood cells, erythrocyte zinc protocells (RBC ) of 21.2% still indicated functional iron porphyrin or soluble transferrin receptor) to evaluate deficiency. Four months after withdrawal of i.v. iron iron metabolism is not absolute. We document this by therapy, the serum ferritin level decreased to 175 mg/l. five exemplary cases illustrating various dilemmas of There was a further decrease of the transferrin saturathe treatment with i.v. iron saccharate and the diÃculty tion and a further increase of the percentage of hypoof assessing the role of iron as a factor limiting the chromic RBC. The rHuEpo dosage necessary to keep response to rHuEpo. These cases are not meant to target haemoglobin between 10 and 12 g/dl increased indicate that problems and exceptions are the rule, but from 110.5 to 150.9 units/kg body weight/week. to sensitize the reader that not everything is as simple
The serum levels of sTFR increased from 1.88 to as indicated by textbook wisdom.
2.63 mg/ml.
Case reports
Patient 2 (Table 2) After more than 12 months of rHuEpo and i.v. iron We report on five patients ( 4 female, 1 male) aged saccharate therapy (total iron dosage 2400 mg), the 64±8 years (mean values±SEM ) undergoing regular serum ferritin value of patient 2 was 1220 mg/l and the haemodialysis therapy for 63±35 months (range transferrin saturation was 28.7%. Nevertheless, a high 20-204). Three patients suÂered from diabetic nephropercentage of hypochromic RBC persisted (12.7). Four months after iron withdrawal there was a marked Correspondence and oÂprint requests to: G. Sunder-Plassmann MD, decrease of the transferrin saturation (11.8%) despite (Table 3) transferrin saturation was 29.4%. However, the percentage of hypochromic RBC was 17.7. Four months After more than 12 months of rHuEpo and i.v. iron after withdrawal of iron supplementation, the serum saccharate therapy (total iron dosage 2040 mg) patient ferritin concentration remained high (746 mg/l ) and 3 had a normal serum ferritin value ( 191 mg/l ) associthe transferrin saturation was >20%. The percentage ated with a very low percentage of hypochromic RBC of hypochromic RBC remained high (25.4). The ( 0.7). Nevertheless, the transferrin saturation was only dosage for rHuEpo remained constant before and after 9.5%. This patient developed absolute iron defiiron withdrawal (174.8 vs 163.6 units/kg b.w./week). ciency 3 and 4 months after withdrawal of iron
The soluble transferrin receptor was 1.88 mg/ml during supplementation (serum ferritin 43.0 and 35.3 mg/l ).
iron supplementation and 2.00 mg/ml 4 months after However, the percentage of hypochromic RBC withdrawal of iron therapy. remained <1%. Surprisingly, the rHuEpo dosage necessary to keep target haemoglobin between 10 and 12 g/dl remained constant (46.9 vs 46.9 units/kg Patient 5 (Table 5) b.w./week). The C-reactive protein value was below the detection limit (<0.5 mg/dl ) during the time period After more than 12 months of rHuEpo and i.v. iron saccharate therapy (total iron dosage 1920 mg) patient of investigation. The soluble transferrin receptor increased from 1.74 to 2.53 mg/ml. 5 displayed a serum ferritin value of 859 mg/l. The transferrin saturation at this time was 23.6%. The (21.5±3.8%, range 9.5-29.4%). However, two of the five patients investigated had a transferrin saturation percentage of hypochromic RBC was 2.0. Four months after withdrawal of i.v. iron, transferrin saturation <20% even after >12 months of intensive i.v. iron therapy. Furthermore, mean values for the percentage decreased to <10% but the percentage of hypochromic RBC remained <5. During withdrawal of i.v. iron of hypochromic RBC were 10.9±4.1 (range 0.7-21.2%), but two of the five patients had therapy, the rHuEpo dosage increased 4.5-fold (from 38.1 to 169.8 units/kg b.w./week) and the sTFR from RBC<10%. After 4 months of iron withdrawal, the serum iron, ferritin and transferrin saturation 1.78 to 2.68 mg/ml.
Haemoglobin and red blood cell concentration as decreased, whereas the percentage of hypochromic RBC and the soluble transferrin receptor increased. At well as iron parameters and rHuEpo dosage obtained from the five haemodialysis patients investigated is the end of the study, four of five patients had a transferrin saturation <20%. One patient developed summarized in Table 6 . The haemoglobin concentration, the RBC distribution width, the reticulocytes, absolute iron deficiency (serum ferritin <100 mg/l ).
The percentage of hypochromic red blood cells of the and the serum transferrin values remained constant. After more than 12 months of rHuEpo and i.v. iron four patients with transferrin saturation <20% was in the range between 0.7 and 52.6%. In all five patients saccharate treatment the mean serum ferritin value was high ( 851±185 mg/l, range 191-1220 mg/l ) and the rHuEpo dosage necessary to keep target haemoglobin constant increased during 4 months of iron the serum transferrin saturation was >20% withdrawal from 86.2±25.4 to 154.1±56.1 units/kg for hypochromic RBC was 10.9±4.1% after more than 12 months of intensive i.v. iron saccharate therapy in b.w./week (n.s.). combination with rHuEpo. Three of these five haemodialysis patients displayed hypochromic RBC>10% Discussion (normal <2.5%). The hypochromic RBC is defined as an individual red cell containing a haemoglobin conOur observation on five chronically uraemic patients centration of <28 g/dl. undergoing regular haemodialysis treatment demonAfter more than 12 months of intensive iron therapy strates the limitations of available diagnostic proced-(total iron saccharate dosage 2040 mg) patient 3 had ures in evaluating iron status of individual dialysis a serum ferritin of 191 mg/l, but a transferrin saturation patients.
of 9.5% that was compatible with functional iron deficiency. In contrast a percentage of hypochromic RBC of 0.7% in combination with a serum ferritin of Plasma iron 191 mg/l suggested adequate iron status. Four months The diagnostic value of measuring plasma iron concen-after withdrawal of iron, the serum ferritin concentratrations is limited because of circadian variation, i.e. tion decreased to 35.3 mg/l (Table 3 ) suggesting absochanges of iron concentration during the day. lute iron deficiency. The percentage of hypochromic Furthermore, iron levels might be influenced by various RBC was 0.9%. Furthermore, the rHuEpo dosage diseases or by inadequate collection and processing of necessary to keep target haemoglobin constant blood samples.
remained at 49.9 units/kg b.w./week. These data suggest that a serum ferritin level of 100 mg/l is not Transferrin necessarily the minimum level to indicate iron deficiency for every haemodialysis patient, especially if the Transferrin is often low in uraemic patients, indicating C-reactive protein concentration is normal. malnutrition [7 ] . The plasma iron transport is reflected by the transferrin saturation which in turn depends on serum iron levels. Since iron levels vary significantly Serum ferritin throughout the day, diurnal variation of transferrin
In the pre-rHuEpo era it was proposed that the minsaturation between 15 and 70% has been observed [8] .
imal level of serum ferritin to indicate iron deficiency A long series of review articles on iron management in chronic renal failure patients should be raised to have carried forward the statement that a transferrin 80 mg/l [11] [12] [13] [14] . At the beginning of the rHuEpo era, saturation <20% indicates iron deficiency even in the the cut-oÂ value was initially set at 30 mg/l [15 ] , but presence of normal or elevated serum ferritin levels.
was rapidly adjusted to 100 mg/l [16 ] . In one of the However, there is a remarkable lack of clinical data to first studies on intensive i.v. iron therapy of haemodiasupport this argument. The variability of measured lysis patients, Allegra et al. [17 ] suggested a ferritin transferrin saturation values is considerable, and a cut-oÂ level of 191 mg/l. As awareness of functional single value is fairly uninformative. Therefore, it is iron deficiency increased, this cut-oÂ level of approxiinappropriate to base the diagnosis of functional iron mately 200 mg/l ferritin was also proposed by other deficiency on a single measurement of <20%. The authors [18] [19] [20] [21] [22] . In patients with normal kidney funcstudy of Lynn et al. [9 ] demonstrates that a transferrin tion, the serum ferritin levels for premenopausal saturation <20% is common in haemodialysis. It has females are 8-120 mg/l, for postmenopausal females been shown that low initial transferrin saturation does 30-300 mg/l, and for males 18-440 mg/l [23 ]. It is quite not predict a poor response to erythropoietin in haemopossible that ferritin levels <100 mg/l are adequate in dialysis patients, and may even fail to increase with individual haemodialysis patients if the hypochromic intravenous iron dextran. Thirteen haemodialysis RBC are <5%. Braun and co-workers [unpublished patients had an initial transferrin saturation of 12.6% findings] also described individual haemodialysis and a final transferrin saturation of 14.1% after patients with a serum ferritin <100 mg/l and hypoch-2384 mg of i.v. iron dextran supplementation. Serum romic RBC <5%. ferritin increased from 175 to 332 mg/l [9]. The mean Measurement of the percentage of hypochromic baseline transferrin saturation in our study was initially RBC may provide a more sensitive method of detecting 21.5±3.8% and decreased to 12.3±2.4% within 4 iron-deficient erythropoiesis than the transferrin satmonths of iron withdrawal (Table 6 ). Two of the five uration [10]. However, after more than 12 months of haemodialysis patients studied showed a transferrin intensive i.v. iron saccharate therapy in a combination saturation <20% in the presence of serum ferritin with rHuEpo patient 1 had a serum ferritin of 806 mg/l values of 806 or 191 mg/l. and corresponding hypochromic RBC of 21.2% (Table 1 ). The serum ferritin of patient 2 was 1220 mg/l, Percentage of hypochromic RBC whereas the corresponding hypochromic RBC were 12.7% (Table 2 ) . Finally, patient 4 had a serum ferritin Macdougall et al.
[10] introduced the measurement of the percentage of hypochromic RBC in renal failure of 1180 mg/l and hypochromic RBC of 17.7% (Table 4 ) . In all patients in whom the hypochromic patients in whom classical indicators failed to detect functional iron deficiency. However, the mean value red cell percentage was high, C-reactive protein meas-urement was normal (<0.5 mg/dl ). Therefore occult drawal or continuation of iron therapy. Our observations confirm what is already known about the infection or inflammatory disease is not the explanation for why the elevated percentage of hypochromic RBC limitations of the available measurements of iron status. Nevertheless, it is remarkable that the haemodid not respond to intravenous iron administration. Iron supplementation in these patients was stopped in globin concentration could be kept constant in all five patients, irrespective of the various discrepancies order to avoid iron overload. According to Eschbach [24 ] serum ferritin should be maintained above 300 mg/l observed in their iron status parameters, thanks to a substantial increase of rHuEpo dosages in three of five but not exceed 1000 mg/l. In contrast, recent data from our laboratory [unpublished work] demonstrate pro-patients. The possibility exists of simply ignoring the iron parameters in patients with conflicting results of found impairment of polymorphonuclear leukocytes in haemodialysis patients with a serum ferritin level iron-status surveillance and to increase progressively the dose of rHuEpo until target haemoglobin is reached >650 mg/l even if the serum transferrin saturation is <20% (functional iron deficiency).
or maintained. However, in this case the patients are at risk of developing severe iron deficiency. On the All of our patients received treatment with intravenous rHuEpo. The doses required may diÂer for patients other hand, continuation of iron therapy may entail the risk of iron overtreatment complicated by infection, on subcutaneous administration, particularly during 4 months of i.v. withdrawal. Therefore we cannot ignore cardiovascular disease, and/or malignancy. that the percentage of hypochromic RBC will diÂer between patient populations that are treated diÂerently.
